+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Immune Disorders Drugs Market Research Reports

Allergic Conjunctivitis - Pipeline Insight, 2024 - Product Thumbnail Image

Allergic Conjunctivitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Allergic Rhino-Conjunctivitis - Pipeline Insight, 2024 - Product Thumbnail Image

Allergic Rhino-Conjunctivitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Hereditary Angioedema - Pipeline Insight, 2024 - Product Thumbnail Image

Hereditary Angioedema - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 90 Pages
  • Global
From
Neutropenia - Pipeline Insight, 2024 - Product Thumbnail Image

Neutropenia - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Chronic Spontaneous Urticaria - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic Spontaneous Urticaria - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
COSENTYX Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

COSENTYX Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • March 2024
  • 30 Pages
  • Global
From
PD-1 and PD-L1 Inhibitors - Competitive Landscape, 2024 - Product Thumbnail Image

PD-1 and PD-L1 Inhibitors - Competitive Landscape, 2024

  • Report
  • February 2024
  • 450 Pages
  • Global
From
TRS01 Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

TRS01 Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • February 2024
  • 30 Pages
  • Global
From
REGN4461 Market Size, Forecast, and Emerging Insight - 2032 - Product Thumbnail Image

REGN4461 Market Size, Forecast, and Emerging Insight - 2032

  • Report
  • February 2024
  • 30 Pages
  • Global
From
Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin-18 (IL-18) Inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • February 2024
  • 60 Pages
  • Global
From
Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin-2 (IL-2) Inhibitor - Pipeline Insight, 2024

  • Drug Pipelines
  • February 2024
  • 60 Pages
  • Global
From
Toll-Like Receptor 3 (TLR-3) Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Toll-Like Receptor 3 (TLR-3) Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
RIPK1 inhibitor - Pipeline Insights, 2024 - Product Thumbnail Image

RIPK1 inhibitor - Pipeline Insights, 2024

  • Clinical Trials
  • January 2024
  • 50 Pages
  • Global
From
C-X-C Chemokine Receptor (CXCR) Inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

C-X-C Chemokine Receptor (CXCR) Inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
P selectin inhibitors - Pipeline Insight, 2024 - Product Thumbnail Image

P selectin inhibitors - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
From
From
From
Lupus Nephritis - Epidemiology Forecast - 2032 - Product Thumbnail Image

Lupus Nephritis - Epidemiology Forecast - 2032

  • Report
  • January 2024
  • 84 Pages
  • Global
From
Interleukin 8 receptor antagonists - Pipeline Insight, 2024 - Product Thumbnail Image

Interleukin 8 receptor antagonists - Pipeline Insight, 2024

  • Drug Pipelines
  • January 2024
  • 60 Pages
  • Global
From
Loading Indicator

The Immune Disorders Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs to treat immune system disorders. These drugs are used to treat a variety of conditions, including allergies, asthma, autoimmune diseases, and cancer. Immune Disorders Drugs are designed to target specific parts of the immune system, such as cytokines, antibodies, and T-cells, to reduce inflammation and improve the body's ability to fight off infection. The Immune Disorders Drugs market is highly competitive, with many large pharmaceutical companies competing for market share. Some of the major players in the market include AbbVie, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. These companies are constantly researching and developing new drugs to treat immune system disorders, as well as improving existing treatments. Show Less Read more